PDCD1 and cancer: Overall, our pML model developed by focusing on common clinical features is a feasible, reliable, efficient, easy-to-use model in clinical practice to predict the risk for irHAEs associated with a PD-1 or PD-L1 inhibitor in patients with cancer.